<DOC>
	<DOCNO>NCT00957203</DOCNO>
	<brief_summary>Patients Parkinson 's disease complete prior double-blind study 6002-009 eligible enter long-term study . The purpose study evaluate safety efficacy KW-6002 administer long-term patient advance Parkinson 's disease treat levodopa .</brief_summary>
	<brief_title>Long-Term Safety Study KW-6002 ( Istradefylline ) Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>1 . Be willing able give write informed consent 2 . Completion study 6002009 1 . Minimental status examination score 23 less 2 . Less 70 % compliance study 6002009 3 . Emergency deviation study 6002009 4 . Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end dose wear</keyword>
	<keyword>OFF time</keyword>
</DOC>